⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AVIR News
Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
globenewswire.com
AVIR
IoT Device Management Market (2026-2030) Report Now Available, Reveals Why AI-Driven Automation Is Replacing Fragmented, Manual Device Management Workflows
globenewswire.com
IBM
MSFT
AMZN
GOOG
AVT
ARM
BCC
CSCO
CTAS
PTC
SI
TEL
ACN
CDNS
CDW
DXC
INFY
INTC
MRVL
NVDA
QCOM
AMD
NXPI
ON
TXN
ADI
MCHP
LRCX
AMAT
MU
WDC
SE
NOW
CRM
PANW
ZS
FTNT
SNPS
CD
VRSN
GLW
MRTN
AVGO
QTRX
AER
WSO
JAMF
ERIC
CTSH
HPE
HPQ
DELL
LEN
HON
GE
BA
LMT
GD
RTX
NOC
AVIR
ALGN
IDXX
ISRG
REGN
GILD
AMGN
BMY
ABBV
MRK
PFE
JNJ
TMO
ILMN
BIIB
VRTX
AZN
SNY
XOM
CVX
SHEL
T
VZ
TMUS
Avimer Bio and CNIO Advance Protein Cage Design for Targeted Medicine
prnewswire.com
AVIR
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
globenewswire.com
AVIR
Form 8-K
sec.gov
AVIR
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
AVIR
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
globenewswire.com
AVIR
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
globenewswire.com
AVIR
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
globenewswire.com
AVIR
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
globenewswire.com
AVIR